Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
Featured Content from MarketBeat.com
What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller. Date Posted: 5/7/2026. 
Key Points
- Eli Lilly has been clearly winning its GLP-1 battle against Novo Nordisk, but both companies just got a piece of good news
- The Food and Drug Administration's latest proposal looks to curtail certain compounding facilities going forward
- Shares of LLY, NVO, and HIMS all gained on the day of the announcement
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are two weight-loss and diabetes drug stocks that have taken very different paths. Since the start of 2025, LLY is up nearly 30%, while NVO has fallen more than 30%. This reflects the market share Eli Lilly has taken from Novo. In its latest quarter, Eli Lilly reported revenue growth of 56% year over year (YOY). For the full year 2026, the midpoint of Lilly’s guidance implies growth of 28% YOY.
Meanwhile, Novo expects its constant-currency sales to decline by 5% to 13% YOY in 2026, a sharp drop from growth of 36% in 2023. Much of the difference in their revenue growth stems from Lilly’s GLP-1 tirzepatide. Branded as Mounjaro and Zepbound, the drug produces around 47% more weight loss than Novo’s semaglutide. Despite their rivalry, the companies recently received news that both can cheer. The Food and Drug Administration has proposed excluding tirzepatide and semaglutide from its 503B bulk list. Here’s what that could mean for Lilly and Novo going forward. FDA Looks to Stop 503B Compounding for Good—Lilly and Novo ScoreWhen an approved drug is in shortage, the FDA allows 503A compounding pharmacies and 503B outsourcing facilities to compound copies of the drug. After the FDA added tirzepatide and semaglutide to the shortage list in 2022, companies like Hims & Hers Health built businesses around compounding GLP-1s. Hims has used both 503A and 503B facilities to source its drugs in the past. Shortages for both drugs ended between 2024 and 2025, but Hims operated in a legal gray area to keep selling them. According to Pharmacy Times, if the proposal is adopted, it would “foreclose any future pathway” for 503B facilities to compound the drugs, “even in the event of a new shortage designation.” In other words, there would be no going back. For Lilly and Novo, that would be a clear win. Compounders have siphoned off demand for their drugs that would otherwise have gone to them. The proposal would remove the ability of 503B facilities to do that in the future. For 503A, that future opportunity still exists, although it is technically prohibited to sell these drugs under that status now that the shortages are over. Still, Hims clearly shows how regulators have not fully enforced this. Notably, Novo shares rose 4.8% on the day of the April 30 announcement, showing that investors viewed it as a meaningful piece of positive news. Lilly rose 9.8% that day, and although the announcement coincided with the company’s highly impressive earnings report, the news likely added to Lilly’s gains. Hims Gains as Investors Weigh Compounding RegulationFor Hims and Hers, the benefit is more nuanced but still real. The company recently signed a deal with Novo, allowing it to formally sell semaglutide and oral semaglutide. With this proposal, the pool of compounders that Hims competes with would weaken. With its Novo agreement, Hims can sell branded (also known as non-compounded) versions of the company’s GLP-1s. That means the FDA proposal should not limit Hims' ability to sell Novo’s drugs. However, it would affect the ability of some compounders to do the same in the future, putting Hims in a stronger position. In a statement to Reuters, a Hims & Hers spokesperson said the company does not expect the proposal to affect its business. Hims noted that “there are no GLP‑1s compounded by 503B facilities accessible through our platform.” Hims shares rose by approximately 3.2% on the day of the proposal. Hims can also continue to sell Lilly’s drugs. However, the firm does not have the same type of agreement that it has with Novo. Accessing Lilly’s drugs through Hims works more like a referral arrangement, directing users to Lilly. Hims' own announcement says, “Access to Zepbound and Foundayo does not imply a partnership or affiliation with Eli Lilly and Company." Because of that, it is very unlikely that Hims receives any direct financial benefit from offering Lilly’s drugs. However, Hims may still gain or retain members who would otherwise have turned to other telehealth platforms to access Lilly’s treatments. Lilly Continues to Dominate the GLP-1 ArenaOverall, Eli Lilly and Novo should receive additional protection for their valuable GLP-1 drugs. The proposal is not final yet. However, since it came from the FDA itself, it is likely to be enacted. Hims is an under-the-radar winner from the proposal on the semaglutide side, given its formally established relationship with Novo. However, among these names, Eli Lilly is clearly in the strongest position. The company has shown that it does not need to make a deal with Hims like Novo did. Instead, it is capturing the bulk of the gains from its top-performing weight-loss and diabetes medications. |
Post a Comment
Post a Comment